NorthWest Biotherapeutics Inc (NWBO)

[CrashOverride]

The share price ran up heavily into NYAS. It was overbought as longs felt fear of missing out. The shorts and swing traders saw that then Adam Feuerstein published a series of slanderous, borderline criminal tweets, beginning on 5/9, which helped create doubt in the minds of neophyte longs. Panic ensued. Stop losses were hit. I am not happy with the price I paid for shares on 5/6 and 5/9 but ultimately I am focused on the future which will bring exponential returns.

We should all remember 5/10 but it seems some do not given the revisionist history being posited on this forum. Updating clinicaltrials dot gov in 2020 would not have prevented this event because we remain on OTC. Who got us on OTC? The Phase V Short Sellers. Some are trying to blame management when they were simply powerless, during our quiet period with matters before journal editors and drug regulators, to stop those who want to destroy shareholder value.

FINRA does not halt OTC trading for scientific meetings. Some may want to trade on an exchange where the government can step in to stop market operations but we see how that distorts price discovery in China. If there were a regulatory investigation underway then we would not know about it until the conclusion was reached. Claiming that something isn't happening because insight into that private process isn't readily apparent for the outside investor seems irrational.

Management are moving forward with regulatory approval for DCVax. Our share price has held up very well given we are trading on a deregulated manipulated over the counter exchange during a period of macroeconomic decline. Every day this forum features the most irrational framing of where we are as a company. Let's consider the context which we should focus upon right now when talking about events in the past that no longer matter.

Keytruda reaches less than 1% of cancer patients per year yet brings in around $20 billion in global revenue. We have a platform technology that will enhance and surpass the efficacy of such checkpoint inhibitors. The UCLA DCVax Keytruda PolyICLC trials show us that we have unlimited potential upside from our current share price given our NIH-subsidized research arm has a clear path forward to improve the cure of Glioblastoma. Longs should feel confident in their Landmark Trial Results, Innovative Manufacturing, and Global Patent Protection.